Registry of Lobbyists
Version 4 of 28 (2007-03-23 to 2007-10-25) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
Bayer Inc.
77 Belfield Road Toronto, ON M9W 1G6 Canada |
| Telephone number: | 613-295-8406 |
| Fax number: | 416-240-5292 |
| Responsible officer name and position during the period of this registration: | Philip Blake, President and CEO |
| Description of activities: | Bayer Inc. ("Bayer") is a Canadian subsidiary of Bayer AG, an international research-based group with core businesses in health care, crop science, and innovative materials.Headquartered in Toronto, Ontario, Bayer Inc. operates the Bayer Group's HealthCare and MaterialScience businesses in Canada. Bayer CropScience Inc., headquartered in Calgary, Alberta operates as a separate legal entity in Canada. Together, the companies play a vital role in improving the quality of life for Canadians - producing products that fight diseases, protecting crops and animals, and developing high-performance materials for applications in numerous areas of daily life. |
| The client is a subsidiary of the following parent companies: |
Bayer AG
51368 Leverkusen Germany |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Name: | Greg Ball |
| Position title: | Business Head, Institutional |
| Public offices held: | No |
| Name: | Norma Beauchamp |
| Position title: | Business Head, Community |
| Public offices held: | No |
| Name: | Alan Birrell |
| Position title: | Head, Hematology & Cardiology |
| Public offices held: | No |
| Name: | Ute Bockstegers |
| Position title: | CFO and Head of BAP |
| Public offices held: | No |
| Name: | Shurjeel Choudhri |
| Position title: | Head, Medical & Scientific Affairs |
| Public offices held: | No |
| Name: | Jacqueline DeGagne |
| Position title: | Head - Law and Patents |
| Public offices held: | No |
| Name: | Stefan Freeman |
| Position title: | Head - Animal Health Division |
| Public offices held: | No |
| Name: | Doug Grant |
| Position title: | VP - Corporate Affairs |
| Public offices held: | No |
| Name: | Jim Graziadei |
| Position title: | Head - Diagnostics Division |
| Public offices held: | No |
| Name: | Gord Johnston |
| Position title: | Head - Human Resources |
| Public offices held: | No |
| Name: | Daniel Lamothe |
| Position title: | Manager, Strategic Partnerships, Hematology Division |
| Public offices held: | No |
| Name: | Reine Larose |
| Position title: | Director - Government Affairs and Patient Access, Quebec, Atlantic Canada |
| Public offices held: | No |
| Name: | Kory McDonald |
| Position title: | Director, Federal Government Affairs |
| Public offices held: | Yes |
| Name: | Paula Moore |
| Position title: | Director, Financial Services |
| Public offices held: | No |
| Name: | Russ Newsome |
| Position title: | Head - Diabetes Care Division |
| Public offices held: | No |
| Name: | Ernie Springnolo |
| Position title: | Country Representative - Bayer MaterialScience |
| Public offices held: | No |
| Name: | Peter Wyles |
| Position title: | Head - Consumer Care Division |
| Public offices held: | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Agriculture and Agri-Food Canada (AAFC), Environment Canada, Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Members of the House of Commons, Natural Resources Canada (NRCan), Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Senate of Canada | ||||||||||||||||||||||||||
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format | ||||||||||||||||||||||||||
| Subject Matter: Areas of Concern: | Agriculture, Consumer Issues, Education, Employment and Training, Energy, Environment, Fisheries, Forestry, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Trade, Labour, Science and Technology, Taxation and Finance, Transportation | ||||||||||||||||||||||||||
| Subject Matter: Retrospective: | Proposed Amendments to Schedule A of the Food and Drugs Act and other measures to enhance promotion and regulation of self-care products (Regulation) Proposed Implementation of Health Canada?s ?Blueprint for Renewal? and Progressive Licencing System (Policy or Program) Canada?s environmental policy, including measures to address air quality and climate change (Policy or Program) Consultations on Patented Prices Medicines Review Board (PMBRB) mandate and policies (Policy or Program) Parliamentary Review of the Canadian Environmental Protection Act (CEPA) (Legislative Proposal)Study of the Common Drug Review by the House of Commons Standing Committee on Health (Policy or Program) onsultations on the federal Science and Technology strategy, entitled Mobilizing Science and Technology to Canada?s Advantage (Policy or Program) Measures relating to cross-border trade of health care products. (Policy or Program) Consultations relating to Canada?s economic outlook and Federal Budget (Policy or Program) | ||||||||||||||||||||||||||
| Subject Matter: Prospective: | Proposed Amendments to Schedule A of the Food and Drugs Act and other measures to enhance promotion and regulation of self-care products (Regulation) Proposed Implementation of Health Canada?s ?Blueprint for Renewal? and Progressive Licencing System (Policy or Program) Canada?s environmental policy, including measures to address air quality and climate change (Policy or Program) Consultations on Patented Prices Medicines Review Board (PMBRB) mandate and policies (Policy or Program) Parliamentary Review of the Canadian Environmental Protection Act (CEPA) (Legislative Proposal)Study of the Common Drug Review by the House of Commons Standing Committee on Health (Policy or Program) Consultations on the federal Science and Technology strategy, entitled Mobilizing Science and Technology to Canada?s Advantage (Policy or Program) Measures relating to cross-border trade of health care products. (Policy or Program)Consultations relating to Canada?s economic outlook and Federal Budget (Policy or Program) | ||||||||||||||||||||||||||
Details Regarding the Identified Subject Matter
|
|||||||||||||||||||||||||||